By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Aimmune Therapeutics 

8000 Marina Boulevard
Suite 300
Brisbane  California  94005-1884  U.S.A.
Phone: 650-614-5220 Fax: 650-616-0075


SEARCH JOBS

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. Aimmune’s first investigational product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients.


Key Statistics


Email: careers@aimmune.com
Ownership: Public

Web Site: Aimmune
Employees:
Symbol: AIMT
 









Company News
Aimmune (AIMT) Announces Second Quarter 2017 Financial Results 8/9/2017 7:35:42 AM
Aimmune (AIMT)’ Investigational Treatment For Peanut Allergy Featured In Science Translational Medicine Publication On Discovery Of New TH2 Cell Subset Specific To Allergy 8/8/2017 7:26:17 AM
Aimmune (AIMT) Enrolls First Patient In ARTEMIS (ARC010) European Phase III Clinical Trial Of AR101 For The Treatment Of Peanut Allergy 7/5/2017 7:56:08 AM
Aimmune (AIMT) Presents European Phase III PALISADE Screening Data At 2017 European Academy of Allergology and Clinical Immunology (EAACI) Congress 6/20/2017 6:08:35 AM
BIO2017: Aimmune (AIMT) To Provide Corporate Update At The BIO International Convention 6/19/2017 9:02:21 AM
Aimmune (AIMT) To Present Data On Peanut Allergy In Europe At European Academy of Allergology and Clinical Immunology (EAACI) Congress 2017 6/15/2017 8:01:55 AM
Aimmune (AIMT) Reports On Up-Dosing In Its Ongoing Phase III PALISADE Trial Of AR101 For Peanut Allergy 6/13/2017 7:43:42 AM
CoreRx And Aimmune (AIMT) Joint Expansion To Create Pharmaceutical Jobs And Increase The Base Of Scientific Capabilities In The Tampa Bay Area 6/7/2017 10:22:13 AM
Bay Area's Aimmune (AIMT) Opens Up Shop In Florida For Potential Launch Of Its Peanut Allergy Drug 6/7/2017 6:52:26 AM
Aimmune (AIMT) Enrolls First Patient In RAMSES (ARC007), A Phase 3 Clinical Trial Of AR101 For The Treatment Of Peanut Allergy 5/11/2017 8:25:27 AM
123456
//-->